SynthesisFrontiers in oncology2026
Association between elevated multiple circulating biomarkers and short-term mortality in critically ill lung cancer patients: a meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: While traditional circulating biomarkers have demonstrated prognostic value in general lung cancer patients, their short-term predictive value in critical care settings remains unclear. This study aims to systematically evaluate the association between elevated multiple circulating biomarkers and short-term mortality in critically ill lung cancer patients. Methods: This study searched databases including PubMed, Embase, Web of Science, Cochrane Library, and CNKI from inception to February 2026. Literatures that enrolled patients with severe lung cancer, reported data on the association between biomarkers and short-term mortality, and provided relative risks (RR) or convertible data were included. Meta-analysis was conducted using R software with the Hartung-Knapp-Sidik-Jonkman (HKSJ) method for random effects models and robust variance estimation (RVE) to handle correlated effect sizes from the same study. Heterogeneity was assessed, and subgroup analyses, meta-regression, and sensitivity analyses were performed to evaluate pooled effect sizes and publication bias. Results: This study included 9 literatures, extracting 19 studies covering 4,436 critically ill lung cancer patients. The primary meta-analysis using RVE showed that elevated biomarkers were significantly associated with short-term mortality (pooled RR = 1.62, 95% CI: 1.09-2.41, P = 0.022). Among these, 17 studies showed positive associations, with pooled RR = 1.93 (95% CI: 1.50-2.48, P < 0.001). Subgroup analysis revealed significant differences in effect sizes across different outcomes, biomarker types, and geographical regions (all P < 0.01 between subgroups), with the inflammatory biomarker subgroup showing the highest effect size (RR = 2.44). Subgroup analysis by critical illness definition showed that the effect was significant in both ICU-admitted patients (RR = 1.38, 95% CI: 1.07-1.78) and patients with advanced/terminal disease (RR = 2.45, 95% CI: 1.66-3.62). Meta-regression analysis indicated that outcome measures (90-day mortality) and patient region (North America) were significant factors influencing heterogeneity. Sensitivity analysis confirmed the robustness of results. Conclusion: Multi-biomarker detection provides important reference for risk stratification and treatment decision-making in critically ill lung cancer patients. Future clinical practice could combine traditional critical care scoring systems to establish individualized prognostic prediction models based on multiple biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.